Abstract:There is evidence for a hormone/enzyme/extracellular matrix protein cascade involving fibroblastic growth factor 23 (FGF23), a phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX), and a matrix extracellular phosphoglycoprotein (MEPE) that regulates systemic phosphate homeostasis and mineralization. Genetic studies of autosomal dominant hypophosphatemic rickets (ADHR) and X-linked hypophosphatemia (XLH) identified the phosphaturic hormone FGF23 and the membrane metalloprotease PHEX, and investigations of tumor-induced osteomalacia (TIO) discovered the extracellular matrix protein MEPE. Similarities between ADHR, XLH, and TIO suggest a model to explain the common pathogenesis of renal phosphate wasting and defective mineralization in these disorders. In this model, increments in FGF23 and MEPE, respectively, cause renal phosphate wasting and intrinsic mineralization abnormalities. FGF23 elevations in ADHR are due to mutations of FGF23 that block its degradation, in XLH from indirect actions of inactivating mutations of PHEX to modify the expression and/or degradation of FGF23 and MEPE, and in TIO because of increased production of FGF23 and MEPE. Although this model is attractive, several aspects need to be validated. First, the enzymes responsible for metabolizing FGF23 and MEPE need to be established. Second, the physiologically relevant PHEX substrates and the mechanisms whereby PHEX controls FGF23 and MEPE metabolism need to be elucidated. Finally, additional studies are required to establish the molecular mechanisms of FGF23 and MEPE actions on kidney and bone, as well as to confirm the role of these and other potential “phosphatonins,” such as frizzled related protein-4, in the pathogenesis of the renal and skeletal phenotypes in XLH and TIO. Unraveling the components of this hormone/enzyme/extracellular matrix pathway will not only lead to a better understanding of phosphate homeostasis and mineralization but may also improve the diagnosis and treatment of hypo- and hyperphosphatemic disorders.

The Molecular Sociology of NHERF1 PDZ Proteins Controlling Renal Hormone-Regulated Phosphate Transport

Structural factors of RGS14 regulating hormone-dependent phosphate transport mediated by NPT2A

Distinct and overlapping RGS14 and RGS12 actions regulate NPT2A-mediated phosphate transport

PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1–34

FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization

Regulation of FGF23 production and phosphate metabolism by bone–kidney interactions

FGF-23: More than a regulator of renal phosphate handling?

(Pro)renin Receptor Regulates Phosphate Homeostasis in Rats via Releasing Fibroblast Growth Factor-23

Na+/H+ exchanger regulatory factor 1 (NHERF1) directly regulates osteogenesis

“Phosphatonins” and the regulation of phosphorus homeostasis

Phosphate-sensing mechanisms and functions of phosphate as a first messenger

Inorganic phosphate stimulates fibronectin expression in renal fibroblasts

Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation

Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.

FGF23 and disorders of phosphate homeostasis

Fluorescent Ligand-Directed Co-Localization of the Parathyroid Hormone 1 Receptor with the Brush-Border Scaffold Complex of the Proximal Tubule Reveals Hormone-Dependent Changes in Ezrin Immunoreactivity Consistent with Inactivation.

Parathyroid Hormone 1 Receptor Is Essential To Induce Fgf23 Production And Maintain Systemic Mineral Ion Homeostasis

The rice CK2 kinase regulates trafficking of phosphate transporters in response to phosphate levels.

The regulation of FGF23 in phosphate homeostasis and its clinical significance

A role for sirtuin 1 in FGF23 activation following β-glycerophosphate treatment

Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.